Lithium is a widely used and highly effective treatment for mood disorders. However,
a narrow therapeutic index, requiring routine monitoring of serum concentrations,
is one of the clinical disadvantages. The first case of lithium-associated hyperparathyroidism
(LAH) was reported in 1973. Longer duration of treatment is associated with increased
incidence of LAH. 25% of patients on lithium have a thyroid or parathyroid abnormality,
so regular monitoring of renal and endocrine function was recommended in a recent
systematic review and meta-analysis. LAH is almost always caused by a single parathyroid
adenoma. The treatment is parathyroid surgery. The aim of this study was to assess
if calcium and parathyroid hormone levels are routinely checked in patients on lithium
treamtmenttreatment.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Poster 27
Identification
Copyright
© 2017 Published by Elsevier Inc.
